Featured Research

from universities, journals, and other organizations

Anti-Angiogenesis: A New Weapon In Cancer Therapy

Date:
May 6, 1998
Source:
Noonan/russo Communications
Summary:
As reported this week, Dr. Judah Folkman's promising work in cutting off a tumor's blood supply to treat cancer in mice has excited The National Cancer Institute as well as scientists throughout the industry. A novel concept that Folkman began researching 30 years ago, the inhibition of blood supply to tumors seems critical to the removal of tumors and the prevention of metastases.

As reported this week, Dr. Judah Folkman's promising work in cutting off a tumor's blood supply to treat cancer in mice has excited The National Cancer Institute as well as scientists throughout the industry. A novel concept that Folkman began researching 30 years ago, the inhibition of blood supply to tumors seems critical to the removal of tumors and the prevention of metastases.

To date, Folkman's angiostatin and endostatin proteins have completely eradicated tumors while avoiding side effects in mice. This research suggests that mechanisms that inhibit angiogenesis will have potential as cancer therapeutics.

If you are working on a story regarding the breakthrough of anti-angiogenesis for cancer therapy, you might be interested in related work being done by Ribozyme Pharmaceuticals, Inc. (RPI). Through the use of ribozymes, short RNA molecules that are designed to cleave specific RNA sequences and thereby inhibit the synthesis of disease-causing proteins, RPI is using an anti-VEGF receptor ribozyme to inhibit angiogenesis and thus restrain tumor growth. Preclinical studies have indicated efficacy of the ribozyme as an anti-angiogenic agent in multiple animal models in various cancers and in the eye. Most recently, the anti-VEGF receptor ribozyme has demonstrated the ability to inhibit the development of tumor blood vessels in mice bearing Lewis Lung Carcinoma, resulting in the inhibition of both tumor growth and metastasis.

Note to journalists: If you would like to speak with Dr. Ralph Christoffersen of RPI or would like additional information on RPI's anti-angiogenesis program, please call Neil Cohen, ext. 205 or Lara Kaplan, ext, 246, both of Noonan/Russo Communications, 212-696-4455.


Story Source:

The above story is based on materials provided by Noonan/russo Communications. Note: Materials may be edited for content and length.


Cite This Page:

Noonan/russo Communications. "Anti-Angiogenesis: A New Weapon In Cancer Therapy." ScienceDaily. ScienceDaily, 6 May 1998. <www.sciencedaily.com/releases/1998/05/980506075420.htm>.
Noonan/russo Communications. (1998, May 6). Anti-Angiogenesis: A New Weapon In Cancer Therapy. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1998/05/980506075420.htm
Noonan/russo Communications. "Anti-Angiogenesis: A New Weapon In Cancer Therapy." ScienceDaily. www.sciencedaily.com/releases/1998/05/980506075420.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins